Riskpilot← Back to searchSign inGet full accessFenucure Medical ApS
APSActiveCVR 28486871Nymøllevej 50Research and experimental development on natural sciences and engineering · NACE 7210Est. 20051 employeesfenucure.com
Revenue 2024
DKK -873K
-4% vs 2023
EBITDA margin
298.6%
+6% vs 2023
Equity ratio
24.1%
Financial strength
Net profit 2024
DKK -1,5M
+27% vs 2023
| Revenue | DKK -873K | -4% |
| EBITDA | DKK -2,6M | +6% |
| Net profit | DKK -1,5M | +27% |
| Total assets | DKK 3,3M | +125% |
| Equity | DKK 795K | +147% |
| Employees | 1 | — |
Legal name
Fenucure Medical ApS
CVR number
28486871
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14. februar 2005
Share capital
DKK 400.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede
bestyrelse eller af direktøren i forening med bestyrelsesformanden.
Company purpose
Selskabets formål er at drive virksomhed inden for medicinalbranchen, branchen for naturlægemidler og hygiejneprodukter og enhver hermed beslægtet branche efter ledelsens skøn.
Address
Nymøllevej 50
Phone
+4581448132
Email
info@fenucure.com
Website
fenucure.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -2.429 | -1.714 | -1.590 | -912 | -873 |
| Staff expenses | -1.504 | -1.826 | -1.841 | -1.868 | -1.735 |
| EBITDA | -3.932 | -3.541 | -3.431 | -2.780 | -2.608 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -3.932 | -3.541 | -3.431 | -2.780 | -2.608 |
| Net financials | -146 | -115 | -117 | -111 | -174 |
| Profit before tax | -4.078 | -3.655 | -3.549 | -2.891 | -2.782 |
| Tax | -897 | 887 | -0 | -783 | -1.253 |
| Net profit | -3.181 | -4.543 | -3.549 | -2.108 | -1.529 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4.083 | 2.929 | 1.258 | 1.468 | 3.300 |
| Equity | -976 | -2.519 | -3.568 | -1.676 | 795 |
| Long-term debt | 2.250 | 2.659 | 2.563 | 2.492 | 1.602 |
| Short-term debt | 2.810 | 2.789 | 2.263 | 651 | 903 |
| Total debt | 5.060 | 5.448 | 4.825 | 3.144 | 2.505 |
EBITDA margin
-260826800.0%
This company
15.8%
Market median
-1650802632% vs market
20202024
Equity ratio
24.1%
This company
38.2%
Market median
-37% vs market
20202024
Return on equity
-192.3%
This company
18.4%
Market median
-1145% vs market
20202024
Net profit margin
-152900700.0%
This company
8.1%
Market median
-1887663063% vs market
20202024
Asset turnover
-0.26×
This company
1.12×
Market median
-123% vs market
20202024
Debt / equity
3.15×
This company
0.62×
Market median
-408% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
HL Founder | Founder | 2005 |
CH Chief Executive Officer | Chief Executive Officer | 2019 |
| Former (2) | ||
PX Management | Management | 2014 – 2018 |
JS Chief Executive Officer | Chief Executive Officer | 2008 – 2019 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Chairman | 2019 | |
| Board of Directors | 2019 | |
| Board of Directors | 2019 | |
| Board of Directors | 2025 | |
| Board of Directors | 2020 | |
| Former (1) | ||
| Board of Directors | 2019 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 66.67–89.99% | 66.67–89.99% | 2022 | |
| Company | 5–9.99% | 5–9.99% | 2024 | |
| Company | 5–9.99% | 5–9.99% | 2024 | |
| Company | 50–66.65% | 50–66.65% | 2019 | |
| Company | 50–66.65% | 50% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SVONI HOLDING ApS
Fenucure Medical ApS Board members of Fenucure Medical ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Holger Lunden | Founder | 0 companies |
| Philip Xavier Severin Møller | Management | 0 companies |
| Jens Steen Olsen | Chief Executive Officer | 0 companies |
| Christian Hother Sørensen | Chief Executive Officer | 0 companies |
| Nicolai Fink Gundersen | Chairman | 0 companies |
| Jørgen Schönherr | Board of Directors | 0 companies |
| Alex Gundersen | Board of Directors | 0 companies |
| Preben Andersen | Board of Directors | 0 companies |
| Mogens Viktor Madsen | Board of Directors | 0 companies |
| Niels Christian Beck Vase | Board of Directors | 0 companies |